PD-L1 PET/CT imaging scan for cancer patients
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with or suspected to have cancer (or were treated for cancer before)
- Your doctor has already planned a PD-L1 PET/CT scan for you
- You are able to give written informed consent (or a parent/legal guardian can if you cannot)
- You are not pregnant
- You do not have only non-cancerous growths or lesions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special injection (a radioactive tracer) that lights up PD-L1 in your tumors during a PET scan. It helps doctors see which tumors might respond to immunotherapy.
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
This trial uses a special injectable imaging agent (a 'probe') that lights up a protein called PD-L1 on your tumor cells. It helps doctors see your tumors more clearly on a PET scan, which may guide treatment decisions.
This study tests an imaging method that looks for PD-L1 (a protein linked to some cancers) in solid tumors, including gastrointestinal cancers. It may help doctors better see where PD-L1 is in the body using a scan.
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
Hear when a new PD-L1 Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.